Since it is Master's season, I thought I'd go with the golf analogy. The WSJ Health blog reports that as of last month Ranbaxy's generic version of Lipitor is already outselling Pfizer's original drug. It just goes to show the incredible pace at which generics are now able to overtake the innovator product once it comes off patent. Presumably this is due to the tremendous cost savings one can get with a generic.
Incredibly (to me) Ranbaxy only began selling its generic Lipitor (atorvastin) Nov 30th last year and as of the last week in March it sold 17.5 M pills for that week compared to Pfizer's 17.2 M -- at least that is the report according to Wolters Kluer Pharma Solutions. All I can say is WOW!
Ranbaxy may not have the fabled jacket but they do have the GREEN.
Posted by Bruce Lehr Apr 6th 2012.